14 completed, 1 enrolling by invitation, 1 terminated. 12 Phase 3, 1 Not applicable, 1 Phase 1, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 11, Terminated 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Enrolling by invitation 1 |
Follow Edarbi: new trials by email Literature Review of Edarbi trials Research Report on Edarbi
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? Losartan, Valsartan, Azilsartan - Covid19, SARS-CoV Infection | Phase 3 | Terminated | University of British Columbia | 341 | 2020-10-09 | 2023-02-16 |
| A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Participants TAK-491, TAK-491 placebo - Healthy Volunteer | Phase 1 | Completed | Takeda | 64 | 2015-11-20 | 2020-02-05 |
| Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension Azilsartan medoxomil, Valsartan, Azilsartan medoxomil Placebo - Essential Hypertension | Phase 3 | Completed | Takeda | 612 | 2015-08-27 | 2019-03-05 |
| Effect of Azilsartan on Aldosterone in Postmenopausal Females Azilsartan medoximil, Placebo - Hypertension | Not applicable | Completed | University of Chicago | 21 | 2013-01-01 | 2017-11-09 |
| A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone Azilsartan medoxomil/placebo, Azilsartan medoxomil - chlorthalidone - Essential Hypertension | Phase 3 | Completed | Takeda | 507 | 2011-10-01 | 2014-04-23 |
| An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension. Azilsartan medoxomil, Valsartan, Olmesartan - Hypertension | Phase 3 | Completed | Takeda | 1291 | 2008-04-01 | 2011-04-19 |
| Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension Azilsartan medoxomil, Ramipril - Hypertension | Phase 3 | Completed | Takeda | 885 | 2008-01-01 | 2012-11-15 |
| Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension Azilsartan Medoxomil, Valsartan - Hypertension | Phase 3 | Completed | Takeda | 984 | 2007-12-01 | 2012-02-02 |
| Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension Azilsartan Medoxomil and amlodipine, Amlodipine - Hypertension | Phase 3 | Completed | Takeda | 566 | 2007-10-01 | 2011-07-22 |
| Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension Azilsartan medoxomil, Placebo - Hypertension | Phase 3 | Completed | Takeda | 413 | 2007-10-01 | 2011-04-19 |
| Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension Azilsartan medoxomil and chlorthalidone, Chlorthalidone - Hypertension | Phase 3 | Completed | Takeda | 551 | 2007-09-01 | 2011-04-19 |
| A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension Azilsartan medoxomil, Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications., Placebo - Hypertension | Phase 3 | Completed | Takeda | 418 | 2007-06-01 | 2012-01-04 |
| One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension Azilsartan medoxomil with or without add-on chlorthalidone, Azilsartan medoxomil with or without add-on hydrochlorothiazide - Hypertension | Phase 3 | Completed | Takeda | 669 | 2007-06-01 | 2011-04-19 |
| Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension Azilsartan medoxomil and olmesartan, Olmesartan, Placebo - Hypertension | Phase 3 | Completed | Takeda | 1275 | 2007-06-01 | 2011-07-29 |
| Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension Azilsartan Medoxomil, Olmesartan, Placebo - Hypertension | Phase 2 | Completed | Takeda | 449 | 2006-05-01 | 2011-04-19 |
Hypertension (12) · Essential Hypertension (7) · Cardiovascular Diseases (5) · Acute Kidney Injury (1) · Albuminuria (1) · COVID-19 (1) · Coronavirus Infections (1) · Diabetes Mellitus, Type 2 (1) · Hyperkalemia (1) · Obesity (1) · Renal Insufficiency, Chronic (1) · Respiratory Distress Syndrome (1) · Severe Acute Respiratory Syndrome (1) · Shock (1) · Vascular Diseases (1)
Takeda (13) · Baylor Research Institute (1) · University of British Columbia (1) · University of Chicago (1)
United States (11) · Mexico (6) · Argentina (4) · Peru (3) · Bulgaria (2) · Chile (2) · China (2) · Estonia (2) · France (2) · Germany (2) · Netherlands (2) · Poland (2) · Puerto Rico (2) · Serbia (2) · Slovakia (2)
George Bakris, MD (1) · James A Russell, MD (1) · Karen Tran, MD (1)
PMID 21282560, PMID 21272195, PMID 21762358, PMID 25619410, PMID 30175930, PMID 32769878, PMID 39325643